GeneDx to Launch Comprehensive Breast Cancer Genetic Test

          GeneDx to Launch Comprehensive Breast Cancer Genetic Test

  PR Newswire

  GAITHERSBURG, Maryland, June 13, 2013

GAITHERSBURG, Maryland, June 13, 2013 /PRNewswire/ --GeneDx, one of the
world's foremost genetic testing laboratories and a subsidiary of
Bio-Reference Laboratories, Inc. (NASDAQ: BRLI) announced today its intention
to launch a suite of comprehensive genetic tests for inherited cancers
including BRCA1 and BRCA2 genes, given the Supreme Court's ruling in the
Association for Molecular Pathology vs. Myriad Genetics case.

GeneDx, which was the first commercial laboratory to utilize next generation
sequencing technologies to answer meaningful clinical questions in cardiology,
neurology, ophthalmology, among other clinical areas, will now bring its
expertise and reputation for service to inherited cancers and will offer a
27-gene panel for breast and ovarian cancers. GeneDx will also provide next
generation sequencing based multi-gene panels for gastrointestinal and
colorectal cancers, pancreatic cancer, endometrial cancer and renal cell
carcinoma. The Company has indicated that it intends to introduce all of these
panels as early as August 1, 2013.

According to Sherri Bale, Ph.D., a founder and the Managing Director of
GeneDx, "These panels will provide an efficient and cost-effective approach to
identifying the genetic basis of inherited cancer. For breast/ovarian cancer
particularly, it will be a more sensitive approach than testing only the BRCA1
and BRCA2 genes alone. Over the past decade, research has identified many
genes associated with hereditary cancers. Some of these genes play a role in
more than one type of cancer, and in most types of cancer several genes may be
characterized as causative. Determining which genes and the order in which to
test them can be complex, expensive and time consuming. GeneDx, therefore, has
developed comprehensive panels to facilitate testing of all the important
genes associated with inherited cancers in a manner that provides rapid and
accurate results and at typically no additional cost when compared to testing
for a single gene."

GeneDx has distinguished itself and gained the trust of the genetics community
for its clinical and scientific expertise and experience. Founded in 2000 by
geneticists and still managed today by geneticists, GeneDx started offering
Whole Exome Sequencing in 2012 to help end the diagnostic odyssey for families
who for years have been looking for a molecular diagnosis. Currently, GeneDx
offers testing for more than 350 genetic disorders, and has over 30
board-certified geneticists and genetic counselors on staff available to
physicians to address their concerns and questions about genetic testing.

About Bio-Reference Laboratories (NASDAQ = BRLI), Inc. and GeneDx BRLI is the
fourth largest full service laboratory in the United States, primarily a
clinical testing laboratory servicing physician offices with concentrations in
the focused markets of esoteric testing, molecular diagnostics, anatomical
pathology, women's health and correctional health care. BRLI is a national
oncology laboratory operating as GenPath. Better science, superior technology
and better service have enabled GenPath to earn a reputation as one of the
premier hematopathology laboratories in the country. BRLI's innovative
technology platform for sexually transmitted infections has enabled it to
expand as a national laboratory in the area of Women's Health. GeneDx, a
wholly owned subsidiary, is the BRLI genetics laboratory and is typically
recognized as the leading laboratory for testing of rare genetic diseases;
GeneDx has now become a technology leader with XomeDx, whole exome sequencing
test, and its Next-Gen sequence offerings that are currently offered in
several disease areas, such as cardiology, neurology, immunology,
ophthalmology and prenatal areas.

Contact: Karen Maurer, PR Liaison, 800-229-5227 x7531,
kmaurer@bioreference.com
 
Press spacebar to pause and continue. Press esc to stop.